Skip to Content

Join the 'Vioxx' group to help and get support from people like you.

Vioxx News

Common Painkillers Tied to Slight Rise in Heart Attack Risk

Posted 10 May 2017 by Drugs.com

TUESDAY, May 9, 2017 – Commonly used painkillers such as Motrin, Advil and Aleve might increase your risk for heart attack, even in the first week of use, a new study suggests. Overall, these drugs and others known as nonsteroidal anti-inflammatory drugs (NSAIDs) increase the risk of a heart attack by 20 to 50 percent, compared with not using them, researchers found. For most people, however, ...

Celebrex May Not Pose Bigger Heart Risk Than Similar Drugs: Study

Posted 14 Nov 2016 by Drugs.com

MONDAY, Nov. 14, 2016 – Some people taking the pain reliever Celebrex may not have a greater risk for heart problems than those taking other nonsteroidal anti-inflammatory drugs (NSAIDs), a new study says. Celebrex (celecoxib) is a COX-2 inhibitor. That's the same class of drugs as Vioxx and Bextra, which were pulled from the market in 2004 and 2005, respectively, because they were linked to ...

Giving the 'Green Light' to Migraine Relief

Posted 17 May 2016 by Drugs.com

TUESDAY, May 17, 2016 – A new study sheds light – literally – on a potential means of easing migraine pain. Researchers in Boston exposed 69 migraine patients to different colors of light. They found that while blue light exacerbated headache pain, a narrow spectrum of low-intensity green light significantly reduced light sensitivity. In some cases, this green light also reduced migraine pain ...

X-Rays May Miss Hip Arthritis, Study Finds

Posted 10 Dec 2015 by Drugs.com

THURSDAY, Dec. 10, 2015 – X-rays don't detect hip arthritis in many patients, resulting in delayed diagnosis and treatment, researchers report. The researchers looked at information from almost 4,500 Americans taking part in two arthritis studies. In one study, only 16 percent of patients with hip pain had X-ray evidence of osteoarthritis in the hip and only 21 percent of those with X-ray ...

Certain Painkillers Tied to Raised Risk of Death After Stroke

Posted 5 Nov 2014 by Drugs.com

WEDNESDAY, Nov. 5, 2014 – Arthritis pain relievers known as COX-2 inhibitors, including Celebrex and Lodine, are associated with an increased risk of dying within a month after a stroke, according to a new study. "This large study from Denmark adds to the prior concerns about COX-2 inhibitors and stroke risks," said Dr. Ralph Sacco, chairman of neurology at the University of Miami Miller School ...

Common Painkillers Tied to Blood Clot Risk, Study Suggests

Posted 24 Sep 2014 by Drugs.com

WEDNESDAY, Sept. 24, 2014 – People who use painkillers called nonsteroidal anti-inflammatory drugs (NSAIDs) – which include aspirin, naproxen (Aleve) and ibuprofen (Advil, Motrin) – may be at increased risk for potentially deadly blood clots, a new study suggests. But the study only showed an association between use of the painkillers and higher clotting risk; it did not prove ...

FDA Medwatch Alert: Vioxx (rofecoxib) - Apr 7, 2005

Posted 7 Apr 2005 by Drugs.com

After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: * The lack of adequate data on the cardiovascular safety of long-term use of Bextra, along with the increased risk of adverse cardiovascular (CV) events in short-term coronary artery bypass surgery ...

FDA Medwatch Alert: Vioxx (rofecoxib) - Jun 15, 2005

Posted 15 Jun 2005 by Drugs.com

FDA has requested that sponsors of all non-steroidal anti-inflammatory drugs (NSAID) make labeling changes to their products. FDA recommended proposed labeling for both the prescription and over-the-counter (OTC) NSAIDs and a medication guide for the entire class of prescription products. All sponsors of marketed prescription NSAIDs, including Celebrex (celecoxib), a COX-2 selective NSAID, have ...

FDA Medwatch Alert: Vioxx (rofecoxib) - Sep 30, 2004

Posted 30 Sep 2004 by Drugs.com

Merck & Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib) from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events (including heart attack and stroke) in patients on Vioxx.  Vioxx is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 for the relief of the signs and ...

FDA Medwatch Alert: Vioxx (rofecoxib) - May 6, 2002

Posted 6 May 2002 by Drugs.com

FDA and Merck strengthened the WARNINGS, PRECAUTIONS, and CLINICAL STUDIES sections of Vioxx labeling to describe new cardiovascular and gastroenterological safety information. This information reflected the results of a prospective, active control study of Vioxx 50 mg daily versus naproxen 500 mg twice daily and from a placebo-controlled trials database. This information should be taken into ...

FDA Medwatch Alert: COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Posted 15 Jun 2005 by Drugs.com

After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer, Inc. to voluntarily withdraw Bextra (valdecoxib) from the market. This request is based on: * The lack of adequate data on the cardiovascular safety of long-term use of Bextra, along with the increased risk of adverse cardiovascular (CV) events in short-term coronary artery bypass surgery ...

Ask a Question

Further Information

Related Condition Support Groups

Pain, Migraine, Period Pain, Dysmenorrhea, Rheumatoid Arthritis, Osteoarthritis

Vioxx Patient Information at Drugs.com